About This Article
Evaluation of postprandial glycemic excursions in patients with type 1 diabetes with three prandial insulins: VIAject™ (Linjeta™), an ultra-fast insulin (UFI); insulin lispro (LIS); and regular human insulin (RHI).
![Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection thumbnail](https://prosciento.com/wp-content/uploads/2022/01/journal-60.png)
Evaluation of postprandial glycemic excursions in patients with type 1 diabetes with three prandial insulins: VIAject™ (Linjeta™), an ultra-fast insulin (UFI); insulin lispro (LIS); and regular human insulin (RHI).